We evaluated the levels of CA 19-9 and CA 125 in the sera of healthy individuals, patients with nonneoplastic diseases known to produce elevated serum concentrations of CA 19-9 and CA 125, and patients with malignant tumours. The serum concentrations determined with an immunoradiometric assay (IRMA) and an immunoluminometric assay (ILMA) were compared. The accuracy was determined (äs far äs this is possible in the absence of reference method values), äs well äs the precision (intra-assay Variation and inter-assay Variation), using internal and external controls.
Introduction
and follow-up after surgical Intervention, in order to detect a possible recurrence of a tumour (4) (5) (6) (7) (8) (9) . The labelling of antibodies in immunological assays with chemiluminescent molecules is another step We evaluated the levels ofCA 19-9 and CA 125 in the towards a routine laboratory free of radioisotopes (l, 2). sera of a selected collective, comprising healthy individAcommon Signal generatingreactionis the oxidationof uals > P atients with non-neoplastic diseases known to aminobutylethylispluminol (6- , ., r>tor /o\ A i· rnetric assay and an immunoluminometric assay were emission of hght at a wavelength of 425 nm (3).-Apph-"i, j ·*,**_· " , , . -, : / V ". compared. The accuracy was determined (äs far äs this cation of the sandwich technique, äs for the immunora-. . , , . , , . The activity of I25 I was measured on a gamma-counter (model Crystal II, Packard, Illinois, USA). The Standard curve of CA 19-9 IRMA was fitted to a cubic spline function (mass action smooth splining), and linear fitting was used for CA 125 IRMA. Chemiluminescence was measured using a CliniLumat (Berthold, Wildbad, Germany). The light signal was integrated over the 5 second interval immediately following the injection of 0.3 ml alkaline peroxide solution and 0.3 ml catalyst solution. The Standard curves in both LIA-mat assays were adjusted with a quadratic spline ftinction after a log/logit transformation of the signal.
Each sample was performed in duplicate and the evaluation of serum specimens was repeated if the coeflBcient of Variation exceeded 10%. Six specimens were used for quality control, three external (Bioref, Mömbris, Germany and Lyphocheck level l and 2, Biorad Laboratories, Hercules CA), and three internal controls (one ILMA kit control and two IRMA kit controls). This correlation varied when the results were subdivided according to the diagnosis. For CA 19-9, the coefficients of correlation were higher than the overall correlation in pancreatic carcinoma (r = 0.96), and were equal in gastrointestinal cancer (r -0.88). The concordance of the concentrations in serum was lower in patients with hepatitis (r = 0.82), liver cirrhosis (r = 0.80), and pancreatitis (0.78), and differed substantially in normal subjects (r = 0.47). For CA 125, a correlation significantly below the overall value was observed in healthy individuals only (r = 0.56).
The detection limits of the assays (calculated äs the lowest value distinguishable from the zero calibrator + 3 S. D.) were 1 .5 kU/1 for both ILMAs, and 2 kU/1 for CA 19-9 IRMA and 3 kU/1 for CA 125 IRMA. 6.4 No data concerning the test specificity are reported, since lipaemic or haemolytic sera were not included in this evaluation.
j Quality control of CA 19-9 l
\ Intrarassay Variation
The intra-assay Variation was estimated from the reproducibility of the examined controls (n = 8), äs well äs from the mean coefficient of Variation of the patient samples (tab. 2). An unacceptably high coefficient of Variation was observed when assaying the Bioref control with CA 19-9 ILMA (CV = 17%).
In serum samples, the reprpducibility of the IRMA and the ILMA was nearly independent of the antigen level at concentrations in the ränge 20-1000 kU/1 (tab. 3).
centration: + 1.3%, CV = 3.7%; n = 8), whereas lower means were observed with the IRMA (internal control low, mean deviation from target concentration: -3.6%, CV = 6.2%; internal Standard high, mean deviation from target concentration: -3.2%, CV = 6.3%; n = 8).
The linearity of the assays was checked by diluting serum specimens of high antigen concentrations (coefficient of correlation > 0.98 in both assays).
Inter-assay Variation
To simulate the Situation in a routine laboratory, interassay Variation was determined by using five different lots (tab. 4).
Accuracy andprecision ofthe internal control samples
Tab. 4 Accuracy and precision of the CA 19-9 controls (n = 8).
When evahiated in the respective assay, the internal controls from the manufacturer were slightly higher than indicated in the ILMA (mean deviation from target conTab. 2 Intra-assay Variation of CA 19-9 using different control specimens (n = 8). Lyphocheck conlrol specimens, analysed without reference values for CA 19-9 ILMA, showed a lot-to-lot reproducibility of < 20% (n = 8) with variations similar to those found for the IRMA (CV < 19%; n = 8). For the Bioref sample, reference ranges below the concentration of 40 kU/1 stated by the manufacturer were established (ILMA: 34.7 ± 6.2 kU/1; IRMA: 26.6 ± 3.7 kU/1; n = 8).
ILMA-control
Quality control of CA 125
Intra-assay Variation
The intra-assay Variation was estimated from the reproducibility of the duplicates from patient samples äs well äs from the controls (tab. 5; n = 8) and was found to be generally < 8% with one exception for each assay.
As for CA 19-9, the concentrations of CA 125 in serum were subdivided into ranges to analyse the precision profile (tab.' 3). The reproducibility of CA 125 IRMA and CA 125 ILMA was found to be nearly independent of the serum levels at concentrations between 20 and 1000 kU/1 (tab. 3).
Accuracy and precision ofthe internal control samples
The internal controls from the manufacturer evaluated in the respective assay were 2.3% below the target value in the ILMA (CV = 9.6%; n = 8) and 2.8% higher in the IRMA (CV = 7%, IRMA control low). The high IRMA control matched perfectly the target value of 110 kU/1 (CV = 5.3%).
The linearity of both assays was checked by diluting serum specimens of high antigen concentrations (coefficient of correlation > 0.99 in both assays).
Tab. 5 Intra-assay Variation of CA 125 using different specimens (n = 8 n. e. = not evaluated
Inter-assay Variation
As for CA 19-9, the investigation was performed with five different kit lots (tab. 6).
Problems were encountered with regärd to the accuracy of the Lyphocheck controls, äs none of the assays matched the target concentrations, whereäs the inter-äs-say reproducibility was acceptable in both assays (CV < 17%, n = 8). CA 125 ILMA performed well with the Bioref control (CV = 10%).
Discussion
We report a comparison of two immunoluminometric assays for CA 19-9 and CA 125 with the established immunoradiometric assays, in which we detennined more than 180 serum samples under routine laboratory conditions. We used five different lots for the determination of the concentrations of CA 125 and CA 19-9 in serum. Therefore, the inter-assay Variation not only includes the between-assay precision of the laboratory, but also the manufacturer's ability to produce tests with high reproducibility.
These data are subject to the limitation that only.8 experiments were performed for the calculation of the quality control. Twenty evaluations would be preferable, but this number was not possible for financial and technical reasons.
In 1990, an evaluation of the chemiluminescence immunoassays CA 15-3, CA 125 and,CA 19-9 (13) reported a CV = 5-8% (inträ-assäy precision) and ä CV = 5-17% (inter-assay precision). This study focused on the precision and accuracy of reference samples and f eported only a few results concerning serum samples from patients. The study by Plebani and co-workers (14) reported an excellent inter-assay Variation of the new method. The correlation in their collective was slightly better for CA 125 (r = 0.99) than for CA 19-9 (r = 0.97), but they used parametric test methods for the statistical evaluation.
Other studies investigated the diagnostic value of CA 125 by comparing enzyme-immunoassays with radioimmunoassays, including more than 100 serum samples (15, 16) . In all cases, the coefficient of correlation was better than r = 0.85, but the slope was found to differ considerably from l for the EIA from Abbott relative to the IRMA from Centocor (slope = 0.75 in the study of Pittaway, (17)) with consequences for the sensitivity of the enzyme-immunoassay, äs well äs for the conversion of the tumour marker concentrations from one System to another. Therefore, the long term Interpretation requires concordant results in different assays. With some exceptions for the low serum concentrations (values < 30 kU/1), we obtained comparable results with both assay Systems.
The fitting of the Standard curve with a spline function after log/logit transformation excludes the zero calibrator of the Standard curve. Using the next calibrator äs the lowest evaluable antigen concentration is problematic, in that lower concentrations cannot be reported äs the authentic value. In the clinical use of tumour markers this is generally not a problem, but could become a statistical one. In correlation analyses, small deviations in the lowest concentration ränge do certainly not falsify sample calculations based on more than 180 samples, but are misleading in the healthy sample (r = 0.47 and 0.56 for CA 19-9 and CA 125, respectively).
The aim of the study was to compare the performance of the assays and particularly the concordance of the serum concentrations. Thus, we did a cross sectional investigation in order to evaluate the maximal nümber of serum specimens instead of a serial follow-up study dealing repeatedly with the same serum matrix. The concordance of the serum concentrations was in contradiction to some results obtained with the external controls. While the internal controls were correct in all assays, problems were encountered in evaluating the accuracy (äs far äs this is possible in the absence of reference method values) of the control sera from Bioref and Lyphocheck.
When this study started, no target values were indicated for Lyphocheck control sera in the CA 19-9 ILMA. It was therefore possible to determine only the inter-assay Variation, which was acceptable at a value of 40 kU/1 and good at a value of 70 kU/1, considering that five different lots were used for the ILMA. Some problems arise from the poor chemical definition of the controls; this concerns the structure of the antigens themselves, äs well äs the poorly defined serum matrix. The Bioref control sample is a pooled serum matrix, but can be used only after establishing appropriate reference intervals after a large nümber of runs. Considerable deviations from the target concentrations were observed in our study. A priority in the field of human tumour markers remains therefore the production of standardised control sera. This would allow the critical examination of small deviations from the target values, in order to evaluate the inter-assay Variation äs well äs the lot-to-lot Variation correctly.
The handling of the assays was nearly identical. A difference inherent in the luminescence assay is that the isoluminol molecule bound to the antibody is consumed during the chemiluminescence reaction rendering repeated measurements impossible.
We conclude that the immunoluminometric assay for CA 125 and CA 19-9 with additional quality control from the manufacturer could be an alternative to the immunoradiometric assay, because the serum values correlate well. At the moment, the performance of the radioimmunoassays is better.
